<DOC>
	<DOCNO>NCT02389543</DOCNO>
	<brief_summary>This open-label , randomized clinical study two stage assess maximum tolerate dose ( MTD ) , efficacy , safety selinexor , lenalidomide , dexamethasone ( SLd ) patient relapsed/refractory ( RR ) multiple myeloma ( MM ) . The stage dose escalation ( Phase 1 ) expansion ( Phase 2 ) .</brief_summary>
	<brief_title>Study Selinexor ( KPT- 330 ) , Lenalidomide , &amp; Dexamethasone Relapsed/Refractory Multiple Myeloma Patients</brief_title>
	<detailed_description>In Phase 1 ( Dose Escalation ) , patient randomize either once-weekly ( Arm A ) twice- weekly ( Arm B ) dose selinexor . Dose escalation perform within arm lenalidomide selinexor determine selinexor MTD arm . Each arm expand approximately 17 patient treat MTD arm . The Sponsor Investigator review MTD , efficacy , safety data Phase 1 determine dose schedule ( Arm A B ) use RP2D dose Expansion Phase . In Phase 2 ( Expansion ) , patient receive MTD dose nominate RP2D continue dose . Patients receive RP2D arm stay Phase 1 dose . Additional patient accrue , need , achieve target population size approximately 34 patient RP2D .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically confirm diagnosis , measurable disease evidence disease progression MM . Relapsed refractory recently receive therapy . Relapsed define documented evidence PD achieve least SD ≥ 1 cycle . Refractory disease define ≤ 25 % response ( i.e. , patient never achieve minimal response well ) progression therapy within 60 day completion therapy . Symptomatic MM , base IMWG guideline . Patients must measurable disease . Smoldering MM . Multiple myeloma express Mprotein FLC ( i.e. , nonsecretory MM exclude ) , quantitative immunoglobulin level use instead . Polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change ( POEMS ) syndrome Active MM involve central nervous system ( CNS ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>KPT-330</keyword>
	<keyword>Selinexor</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed/refractory</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Karyopharm</keyword>
</DOC>